AC Immune (ACIU) Net Income towards Common Stockholders (2016 - 2026)
AC Immune has reported Net Income towards Common Stockholders over the past 11 years, most recently at -$18.9 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 10.7% to -$18.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$82.3 million through Mar 2026, down 41.87% year-over-year, with the annual reading at -$88.1 million for FY2025, 51.65% down from the prior year.
- Net Income towards Common Stockholders was -$18.9 million for Q1 2026 at AC Immune, down from -$18.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $6.4 million in Q3 2024 and troughed at -$25.6 million in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$18.9 million (2023), against an average of -$17.4 million.
- Year-over-year, Net Income towards Common Stockholders soared 137.06% in 2024 and then crashed 412.11% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$19.5 million in 2022, then soared by 72.53% to -$5.3 million in 2023, then crashed by 237.25% to -$18.0 million in 2024, then grew by 0.26% to -$18.0 million in 2025, then dropped by 5.1% to -$18.9 million in 2026.
- Per Business Quant, the three most recent readings for ACIU's Net Income towards Common Stockholders are -$18.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$19.8 million (Q3 2025).